Clinical Trial Detail

NCT ID NCT03179436
Title Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

Advanced Solid Tumor

central nervous system cancer

lung non-small cell carcinoma

lung small cell carcinoma

melanoma

Therapies

MK-1308 + Pembrolizumab

MK-1308

Age Groups: senior adult

No variant requirements are available.